We're moving to rndsystems.com. Come with us!

After August 17, 2026, Novus Biologicals products and services will no longer be available on this website; you will access all products and services on rndsystems.com. Create your R&D Systems online account today.

Blogs for July 2010

Chinese Cancer Study Reveals Three New Genes for Nasopharyngeal Carcinomas

Friday, July 30, 2010 - 08:18

A large percentage of the products in our antibody catalog are used for cancer research. Some oncogenes are expressed in several types of tumor, while others are quite specific. For example, there are several products on our antibody database which target genes specific to nasopharyngeal carcinomas (NPC), such as UBAP1 and MMP9. Recently, a Chinese cancer study, which used no fewer than 10,000 volunteer subjects, uncovered 3 new susceptibility genes for NPC.

Western Blot analysis of UBAP1 expression Western Blot analysis of UBAP1 expression

NPC is a cancer which attacks the epithelial cells of the nasopharynx, the area of the...

Real-time Cell Analysis Throws New Light on GPCR Function

Thursday, July 29, 2010 - 08:16

The G-protein coupled receptor (GPCR) family constitutes one of the largest protein families in the mammalian kingdom, with over 800 proteins so far discovered. Our GPCR antibody catalog covers all 6 classes, with antibodies raised against Metabotropic Glutamate/Pheromone receptors; Rhodopsin-like receptors; Secretin receptors; Fungal Mating Pheromone receptors; cAMP receptors and Frizzled/Smoothened receptors. The majority are of the Class A (Rhodopsin-like) class.

GPCRs are a major focus for antibody suppliers. They are fundamental to many life processes, enabling cells to react to changes in their environment by activating intracellular signalling pathways (generally the cAMP or phosphatidylinositol signal transduction pathways), or by binding extracellular molecules (ligands.) Ligands include hormones, odors, neurotransmitters and light-sensitive chemicals.

...

The Role of LC3 within the Autophagic Pathway

Tuesday, July 27, 2010 - 08:14

We at Novus Biologicals have a broad antibody database covering the area of autophagy - over 1400 reagents in total. Autophagy is the bulk degradation of cytoplasmic components - literally, self-digestion of the cell. Double-membrane vesicles, called autophagosomes, carry unwanted cell components to the lysosomes within an inner autophagic membrane. They then fuse, liberating the autophagic body and its contents into the lumen of the vacuole for degradation. This is a complex process involving at least 16 proteins. LC3, however, is the only one known to form a stable association with the membrane of autophagosomes. It is known to exist in two forms: LC3-I, which is found in the cytoplasm, and LC3-II, which is membrane-bound and is converted from LC3-I to initiate formation and lengthening of the autophagosome. It differs from LC3-I only in the fact that it is covalently...

New DLL4 Vaccine May Prevent Breast Tumors

Monday, July 26, 2010 - 08:10

We at Novus Biologicals have a large antibody database devoted to signalling pathways. These underpin every area of molecular biological research, including cancer. Among our cell signalling antibodies is one targeted to DLL4 (Delta-like protein 4). DLL4 is a homologue of the Drosophila delta gene, known to encode DSL-domain ligands on the Notch signaling pathway. It has been shown to play an important role in regulating the angiogenesis, especially those of malignant tumors.

For a tumor to grow beyond a few millimeters in size, new blood vessels must be grown, or the tumor cells will be starved of nutrients and oxygen. DLL4 plays an important role in this. When a new blood vessel begins to sprout from an existing one, DLL4 is expressed in the tip cells. This blocks neighboring cells from forming new...

Conventional Hybridoma Development Versus Plasmid-Based Genomic Antibody Technology

Friday, July 23, 2010 - 08:06

Most commercially available antibodies produced with traditional immunization technology, using peptides or other immunogens isolated and purified from cell lysates.

Typically, mice are immunized with the antigen in groups, varying the mouse strain and antigen dosage. Pre-immune and immune sera are evaluated and mice showing the best immune response are selected for somatic cell fusion. This is the fusion of antibody-producing lymphocytes with proprietary myeloma cells from a non-antibody producing source, creating a hybridoma.

The hybridoma cells then proliferate, producing a continuous supply of monoclonal antibodies. Hybridomas producing the best performing Abs are then cloned, increasing the likelihood of monoclonality. Although it is the standard technique for monoclonal antibodyproduction, it often results in a poor yield when difficult target antigens are used. Problematic immunogens include transmembrane, conserved, and smaller sized proteins.

...

How does Genomic Antibody Technology Work?

Wednesday, July 21, 2010 - 08:04

Novus Biologicals recently added novel GAT (Genomic Antibody Technology) reagents to our antibody catalog, following the formation of a partnership with SDIX, creators of the technique. SDIX's GAT antibodies represent a totally new way to think about protein immunogens.

GAT utilises bioinformatic analysis to select the optimum amino acid sequence for the target protein. The science of bioinformatics, in which statistical computer programs are used to extract biological information from electronic data provided, has become enormously sophisticated since it was first developed in the 1970s, and is the perfect tool for Genomic Antibody Technology. SDIX's HAWK program chooses the optimal 100 aa sequence to create a native antigen.

The benefits of Genomic Antibody Technology

Monday, July 19, 2010 - 08:00

Novus Biologicals offers an extensive antibody databasecovering all areas of biological research. Recently, we dramatically increased the scope of our antibody catalog by adding over 800 antibodies created  using Genomic Antibody Technology (GAT), through a new partnership with SDIX (Strategic Diagnostics, Inc.). As we begin creating novel GAT reagents of our own, this database will expand still further – as there are many GAT antibodiesstill to be created.

Genomic Antibody Technology has many advantages over conventional immunization techniques, using a totally novel method in which immunoglobulins are produced using only the DNA sequence of the target antigen. The need for recombinant proteins, peptides and natively sourced antigens is eliminated. Not only does this make the entire process of producing antibodies time and cost effective, it also eliminates the possibility of protein denaturation, a common problem during expression and purification.

...

Ago2 antibodies and dicer-independent biogenesis of miRNA

Friday, July 16, 2010 - 07:58

Ago2, also called eIF2C2, antibody is one of 37 reagents targeted to the Argonaute protein family that we at Novus Biologicals have in our antibody catalogue. Argonaute proteins are encoded by genes which play an important role in regulating the control of gene expression by miRNA (microRNA). Recently, a new antibody study showed that the role of Ago2 may be to help generate production of miRNA, rather than simply moderate its function.

Micro RNAs are short, highly conserved RNA molecules that regulate gene expression by binding to complementary 3’ UTR (three prime untranslated regions) of the relevant messenger RNA (mRNA). They were first described in 1993, but it was not until the 2000s that they were recognized as a distinct bio-regulatory group.

Role of RASSF1A in Death Receptor-Dependent Apoptosis

Wednesday, July 14, 2010 - 07:55

Death-receptor apoptosis, or cell death, is essential for cellular growth regulation; its disruption is expressed in a variety of cancers. We at Novus Biologicals are one of the leading antibody suppliersfor apoptosis and cancer research groups, and therefore have a large antibody database targeting death receptor proteins.

RASSF1A (Ras association domain family protein 1A) is a tumor-suppressor gene known to play a key role in death-receptor apoptosis. It is expressed in a range of tissues, among them kidney, pancreas, spleen, thymus, brain, lung, liver, prostate, testis and peripheral blood leukocyte cells. Inhibition or mutation of this gene is linked to a variety of cancers.

RASSF1A expression is inhibited when CpG islands (areas where there are high numbers of cytosine-phosphate-guanine or...

Explaining Genomic Antibody Technology

Monday, July 12, 2010 - 07:50

Recently, we at Novus Biologicals became partners with Strategic Diagnostics Inc (SDIX), one of the largest antibodyproducers in the US. The objective was to extend our antibody database by over 800 of SDIX's polyclonal cancer antibodies, created by their unique Genomic Antibody Technology (GAT) system, as well as creating novel GAT immunoglobulins against targets specific to our own antibody catalog. However, what exactly is GAT, and why is it so superior?

With ever more sophisticated assay testing and data retrieval techniques becoming established in the life sciences arena, it’s obvious the reagents must be of a similar quality. In cancer studies especially, it is alterations in protein structure which scientists are looking for. To separate potential oncogenes from normal, non-cancer causing proteins, it’s important that the targets for which antibodies are developed are as near their natural state as possible.

...

Novus in Europe - Antibody Princesses and iPad Winners

Friday, July 9, 2010 - 14:19

Novus has made quite an appearance at many tradeshows this summer in Europe. At each show, we offered a drawing to win an iPad and presented our Antibody Princesses. The iPad winner at the 7th Federation of European Neuroscience Societies Forum in Amsterdam was Alejandro Garcia (pictured below) and the winner at the 21st Meeting of the European Association for Cancer Research in Oslo was Fabio Cattaneo. Novus’ Antibody Princesses appear at exhibitions and congresses, alerting attendees to the wide variety of high-quality antibody products Novus offers.

Novus’ antibody booth will visit 7 European research conventions this summer, including the Keystone Convention on Innate Immunity, the...


Blog Topics


Archives